Association between active GB virus-C (hepatitis G) infection and HIV-1 disease in Uganda

Human papilloma virus genotype distribution and risk factor analysis amongst reproductive aged women in urban Gambia
Bah Camara, H., Anyanwu, M., Wright, E. and Kimmitt, P.T. 2018. Human papilloma virus genotype distribution and risk factor analysis amongst reproductive aged women in urban Gambia. Journal of Medical Microbiology. 67, pp. 1645-1654.

Efficacy Of The Quadrivalent HPV Vaccine In Cervical Cancer Prevention Strategy In The Gambia
Bah Camara, H., Anyanwu, M., Banja, F., Mboob-Suun, K., Ceesay, F., Wright, E. and Kimmitt, P.T. 2017. Efficacy Of The Quadrivalent HPV Vaccine In Cervical Cancer Prevention Strategy In The Gambia. EUROGIN17. Amsterdam 08 - 11 Oct 2017

A Preliminary Report: Cervical Human Papilloma Virus Genotype Distribution in Reproductive Aged Women Attending Primary Health Care in Urban Gambia
Bah Camara, H., Mboob -Suun, K., Banja, F., Ceesay, F., Anyanwu, M., Wright, E. and Kimmitt, P.T. 2017. A Preliminary Report: Cervical Human Papilloma Virus Genotype Distribution in Reproductive Aged Women Attending Primary Health Care in Urban Gambia. Microbiology Society Annual Conference. Edinburgh 03 - 06 Apr 2017

Prevalance of Ureaplasma parvum and urealyticum in Urban Gambian Women
Bah Camara, H., Noho, A., Sanyang, A., Barrow, E., Wright, E. and Kimmitt, P.T. 2017. Prevalance of Ureaplasma parvum and urealyticum in Urban Gambian Women. Microbiology Society Annual Conference. Edinburgh 03 - 06 Apr 2017

Planning for the unexpected: Ebola virus, Zika virus, what's next?
Welfare, W. and Wright, E. 2016. Planning for the unexpected: Ebola virus, Zika virus, what's next? British Journal of Hospital Medicine. 77 (12), pp. 704-707.

Ebolavirus pseudotypes as antigen surrogates for serological studies
Bentley, E., Mattiuzzo, G., Wash, R., Binter, S., Friedrich, M., Goulding, D., Kellam, P., Page, M. and Wright, E. 2016. Ebolavirus pseudotypes as antigen surrogates for serological studies. International Journal of Infectious Diseases. 53 (Supplement), p. 123.

Exploiting viral pseudotypes for emerging virus research
Grehan, K., Bentley, E., Mather, S., Kinsley, R., Scott, S.D., Wright, E. and Temperton, N.J. 2016. Exploiting viral pseudotypes for emerging virus research. International Journal of Infectious Diseases. 53 (Supplement), p. 8.

Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model
Miller, J.L., Spiro, S.G., Dowall, S.D., Taylor, I., Rule, A., Alonzi, D.S., Sayce, A.C., Wright, E., Bentley, E.M., Thom, R., Hall, G., Dwek, R.A., Hewson, R. and Zitzmann, N. 2016. Minimal In Vivo Efficacy of Iminosugars in a Lethal Ebola Virus Guinea Pig Model. PLoS ONE.

A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D, Lambe, T., Imoukhuede, E.B., Payne, R., Fehling, S.K., Strecker, T., Biedenkopf, N., Krähling, V., Tully, C.M., Edwards, N.J., Bentley, E.M., Samuel, D., Labbé, G., Jin, J., Gibani, M., Minhinnick, A., Wilkie, M., Poulton, I., Lella, N., Roberts, R., Hartnell, F., Bliss, C., Sierra-Davidson, K., Powlson, J., Berrie, E., Tedder, R., Roman, F., De Ryck, I., Nicosia, A., Sullivan, N.J., Stanley, D.A., Mbaya, O.T., Ledgerwood, J.E., Schwartz, R.M., Siani, L., Colloca, S., Folgori, A., Di Marco, S., Cortese, R., Wright, E., Becker, S., Graham, B.S., Koup, R.A., Levine, M.M., Volkmann, A., Chaplin, P., Pollard, A.J., Draper, S.J., Ballou, W.R., Lawrie, A., Gilbert, S.C. and Hill, A.V.S. 2016. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. The New England Journal of Medicine. 374 (17), pp. 1635-1646.

Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis
Wright, E., Benedictis Paola, D., Minola, A., Rota Nodari, E., Aiello, R., Zecchin, B., Salomoni, A., Foglierini, M., Agatic, G., Vanzetta, F., Lavenir, R., Lepelletier, A., Bentley, E., Weiss, R.A., Cattoli, G., Capua, I., Sallusto, F., Lanzavecchia, A., Bourhy, H., Corti, D. and De Benedictis, P. 2016. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Molecular Medicine. 8 (4), pp. 407-421.

Technical considerations for the generation of novel pseudotyped viruses
King, B., Temperton, N.J., Grehan, K., Scott, S.D., Wright, E., Tarr, A.W. and Daly, J.M. 2016. Technical considerations for the generation of novel pseudotyped viruses. Future Virology. 11 (1), pp. 47-59.

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.
Sutherland, K.A., Goodall, R.L., McCormick, A.L., Kapaata, A., Lyagoba, F., Kaleebu, P., Thiltgen, G., Gilks, C.F., Spyer, M., Kityo, C., Pillay, D., Dunn, D. and Gupta, R.K. 2015. Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. AIDS Research and Human Retroviruses. 31 (10), pp. 1032-1037.

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
Sutherland, K.A., Parry, C.M., McCormick, A.L., Kapaata, A., Lyagoba, F., Kaleebu, P., Gilks, C.F., Goodall, R., Spyer, M., Kityo, C., Pillay, D., Gupta, R.K. and DART Virology Group 2015. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. PLoS ONE. 10 (9).

Retroviral Pseudotypes – From Scientific Tools to Clinical Utility
Wright, E., Temperton, N.J. and Scott, S.D. 2015. Retroviral Pseudotypes – From Scientific Tools to Clinical Utility. in: Encyclopedia of life sciences Chichester Wiley. pp. 1-11

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry
Long, J., Wright, E., Molesti, E., Temperton, N. and Barclay, W. 2015. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research. 4 (30).

Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses
Benfield, C., Smith, S.E., Wright, E., Wash, R.S., Ferrara, F., Temperton, N.J. and Kellam, P. 2015. Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses. Journal of General Virology. 96 (5), pp. 991-1005.

Demonstration of viral antibodies by pseudotype virus neutralisation
Wright, E. 2014. Demonstration of viral antibodies by pseudotype virus neutralisation. in: Rupprecht, C. and Nagarajan, T. (ed.) Current laboratory techniques in rabies diagnosis, research and prevention Elsevier. pp. 147-156

Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies
Molesti, E., Wright, E., Terregino, C., Rahman, R., Cattoli, G. and Temperton, N.J. 2014. Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. Journal of Immunology Research. 2014, p. Article ID 457932.

Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation-assay based diagnostic kit
Mather, S., Wright, E., Scott, S. and Temperton, N.J. 2014. Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation-assay based diagnostic kit. Journal of Virological Methods. 210, pp. 51-58.

Chicken IFITM3 restricts influenza viruses and lyssaviruses in vitro
Smith, S.E., Gibson, M.S., Wash, R.S., Ferrara, F., Wright, E., Temperton, N.J., Kellam, P. and Fife, M. 2013. Chicken IFITM3 restricts influenza viruses and lyssaviruses in vitro. Journal of Virology. 87 (23), pp. 12957 -12966.

Current progress with serological assays for exotic emerging/re-emerging viruses
Mather, S., Scott, S., Temperton, N.J., Wright, E., King, B. and Daly, J.M. 2013. Current progress with serological assays for exotic emerging/re-emerging viruses. Future Virology. 8 (8), pp. 745-755.

Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans
Both, L., van Dolleweerd, C., Wright, E., Banyard, A.C., Bulmer-Thomas, B., Selden, D., Altmann, F., Fooks, A.R. and Ma, J.K.C. 2013. Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB Journal. 27 (5), pp. 2055-2065.

Development of a pseudotype-based neutralisation assay kit for in-field vaccine evaluation and sero-surveillance of highly pathogenic viruses
Temperton, N.J., Mather, S., Scott, S. and Wright, E. 2013. Development of a pseudotype-based neutralisation assay kit for in-field vaccine evaluation and sero-surveillance of highly pathogenic viruses. Influenza 2013: One Influenza, One World, One health. Oxford, UK September 2013

Development of a pseudotype neutralisation assay-based diagnostic kit for in-field vaccine evaluation and serosurveillance for highly pathogenic viruses
Mather, S., Temperton, N.J., Wright, E. and Scott, S. 2013. Development of a pseudotype neutralisation assay-based diagnostic kit for in-field vaccine evaluation and serosurveillance for highly pathogenic viruses. Society For General Microbiology Spring Meeting. Manchester, UK March 2013

Investigating the antibody neutralisation potential of a rabies virus lentiviral pseudotype: an international inter-laboratory trial
Healy, D.M., Horton, D.L., Banyard, A.C., Wright, E., Goddard, T., Evans, J., McElhinney, L.M. and Fooks, A.R. 2013. Investigating the antibody neutralisation potential of a rabies virus lentiviral pseudotype: an international inter-laboratory trial. Society For General Microbiology Spring Meeting. Manchester, UK March 2013

The lyssavirus glycoprotein: how significant are the currently characterised antigenic sites in the induction of neutralising antibodies?
Evans, J., Wright, E., Easton, A., Fooks, A.R. and Banyard, A.C. 2013. The lyssavirus glycoprotein: how significant are the currently characterised antigenic sites in the induction of neutralising antibodies? Society For General Microbiology Spring Meeting. Manchester, UK March 2013

Investigating the functionality and antigenicity of chimeric lyssavirus glycoproteins and their neutralisation profiles
Evans, J., Wright, E., Easton, A., Fooks, A.R. and Banyard, A.C. 2013. Investigating the functionality and antigenicity of chimeric lyssavirus glycoproteins and their neutralisation profiles. 15th International Negative Strand Virus Meeting. Granada, Spain June 2013

Investigating the functionality and antigenicity of chimeric lyssavirus glycoproteins and their neutralisation profiles
Evans, J., Wright, E., Easton, A., Fooks, A.R. and Banyard, A.C. 2013. Investigating the functionality and antigenicity of chimeric lyssavirus glycoproteins and their neutralisation profiles. Pseudotype viruses: applications and troubleshooting. London, UK October 2013

Characterization of a monoclonal antibody cocktail for human rabies prophylaxis
Both, L., van Dolleweerd, C., Banyard, A.C., Wright, E., Fooks, A.R. and Ma, J.K.C. 2013. Characterization of a monoclonal antibody cocktail for human rabies prophylaxis. Pseudotype viruses: applications and troubleshooting. London, UK October 2013

Monoclonal antibodies for prophylactic and therapeutic use against viral infections
Both, L., Banyard, A.C., van Dolleweerd, C., Wright, E., Ma, J.K.C. and Fooks, A.R. 2013. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 31 (12), pp. 1553-1559.

Single domain antibody multimers confer protection against rabies infection
Boruah, B.M., Liu, D., Ye, D., Gu, T.J., Jiang, C.L., Qu, M., Wright, E., Wang, W., He, W., Liu, C. and Gao, B. 2013. Single domain antibody multimers confer protection against rabies infection. PLoS ONE. 8 (8), p. e71383.

The construction of chimeric rabies virus glycoproteins rescues Arctic-like rabies pseudovirus production
Bentley, E., Ali, R., Horton, D.L., Banyard, A.C. and Wright, E. 2013. The construction of chimeric rabies virus glycoproteins rescues Arctic-like rabies pseudovirus production. Pseudotype viruses: applications and troubleshooting. London, UK October 2013

The construction of chimeric rabies virus glycoproteins rescues Arctic-like rabies pseudovirus production
Ali, R., Horton, D.L., Banyard, A.C. and Wright, E. 2013. The construction of chimeric rabies virus glycoproteins rescues Arctic-like rabies pseudovirus production. Society For General Microbiology Spring Meeting. Manchester, UK March 2013

Henipavirus neutralising antibodies in an isolated island population of African fruit bats
Peel, A.J., Baker, K.S., Crameri, G., Barr, J.A., Hayman, D.T.S., Wright, E., Broder, C.C., Fernández-Loras, A., Fooks, A.R., Wang, L.F., Cunningham, A.A. and Wood, J.L.N. 2012. Henipavirus neutralising antibodies in an isolated island population of African fruit bats. PLoS ONE. 7 (1), p. e30346.

Investigating antigenic epitopes on the lyssavirus glycoprotein
Evans, J., Wright, E., Fooks, A.R., Easton, A. and Banyard, A.C. 2012. Investigating antigenic epitopes on the lyssavirus glycoprotein. Society For General Microbiology Spring Meeting. Dublin 2012

Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans
Wright, E., Mugaba, S., Grant, P., Parkes-Ratanshi, R., Van der Paal, L., Grosskurth, H. and Kaleebu, P. 2011. Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans. PLoS ONE. 6 (5), p. e19902.

Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1
McCormick, A.L., Parry, C.M., Crombe, A., Goodall, R.L., Gupta, R.K., Kaleebu, P., Kityo, C., Chirara, M., Towers, G.J. and Pillay, D. 2011. Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1. Antimicrobial Agents and Chemotherapy. 55 (4), pp. 1806-1809.

CL-184, a combination of two human monoclonal antibodies, for use as a vaccine for the potential postexposure prophylaxis of rabies
Wright, E. 2011. CL-184, a combination of two human monoclonal antibodies, for use as a vaccine for the potential postexposure prophylaxis of rabies. Thomson Reuters.

Characterization of a plant-derived monoclonal antibody cocktail for human rabies prophylaxis
Both, L., van Dolleweerd, C., Banyard, A.C., Wright, E., Fooks, A.R. and Ma, J.K.C. 2011. Characterization of a plant-derived monoclonal antibody cocktail for human rabies prophylaxis. Rabies In The Americas XXII. San Juan, Puerto Rico 2011

Characterization of a monoclonal antibody cocktail for human rabies prophylaxis
Both, L., van Dolleweerd, C., Banyard, A.C., Wright, E., Fooks, A.R. and Ma, J.K.C. 2011. Characterization of a monoclonal antibody cocktail for human rabies prophylaxis. 1. 4th International Conference in Plant-Based Vaccines and Antibodies. Porto, Portugal 2011

Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine-Lamivudine plus Nevirapine and Zidovudine-Lamivudine plus Abacavir
Ndembi, N., Goodall, R.L., Dunn, D.T., McCormick, A.L., Burke, A., Lyagoba, F., Munderi, P., Katundu, P., Kityo, C., Robertson, V., Yirrell, D.L., Walker, A.S., Gibb, D.M., Gilks, C.F., Kaleebu, P. and Pillay, D. 2010. Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine-Lamivudine plus Nevirapine and Zidovudine-Lamivudine plus Abacavir. The Journal of Infectious Diseases. 201 (1), pp. 106-113.

The efficacy of current vaccines and novel Nanobody-based antivirals against highly pathogenic rabies and lyssaviruses
Wright, E., Hultberg, A., Rosseels, V., Vaughan, A., Saunders, M., Koenders, M., Verrips, T., Fooks, A.R., van Gucht, S., Weiss, R.A., de Haard, H.J. and Vanlandschoot, P. 2010. The efficacy of current vaccines and novel Nanobody-based antivirals against highly pathogenic rabies and lyssaviruses. Society For General Microbiology Spring 2010 Meeting. Edinburgh, UK 2010

The efficacy of current rabies vaccines and novel Nanobody®-based antivirals against highly pathogenic phylogroup -1 and -2 members of the Lyssavirus genus
Wright, E., Hultberg, A., Rosseels, V., Vaughan, A., Saunders, M., Koenders, M., Verrips, T., Fooks, A.R., Vanlandschoot, P., Weiss, R.A., van Gucht, S. and de Haard, H.J. 2010. The efficacy of current rabies vaccines and novel Nanobody®-based antivirals against highly pathogenic phylogroup -1 and -2 members of the Lyssavirus genus. Rabies In The Americas XXI. Guadalajara, Mexico 2010

Development of a novel serological assay for the detection of rabies virus neutralising antibodies using lentiviral pseudotypes
Armson, B.L., Wright, E., McElhinney, L.M., Banyard, A.C., Goddard, T., Healy, D.M., Voller, K., Weiss, R.A. and Fooks, A.R. 2010. Development of a novel serological assay for the detection of rabies virus neutralising antibodies using lentiviral pseudotypes. 4th Annual Meeting EPIZONE. Saint Malo, France 2010

Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses
Wright, E., Hayman, D.T.S., Vaughan, A., Temperton, N.J., Wood, J.L.N., Cunningham, A.A., Suu-Ire, R., Weiss, R.A. and Fooks, A.R. 2010. Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology. 408 (2), pp. 183-189.

A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa
Wright, E., McNabb, S., Goddard, T., Horton, D.L., Lembo, T., Nel, L.H., Weiss, R.A., Cleaveland, S. and Fooks, A.R. 2009. A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa. Vaccine. 27 (51), pp. 7178-7186.

Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st century
Fooks, A.R., Johnson, N., Freuling, C.M., Wakeley, P.R., Banyard, A.C., McElhinney, L.M., Marston, D.A., Dastjerdi, A., Wright, E., Weiss, R.A. and Muller, T. 2009. Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st century. PLoS Neglected Tropical Diseases. 3 (9), p. e530.

A robust lentiviral pseudotype neutralisation assay for rabies and lyssavirus serology
Wright, E., Temperton, N.J., Weiss, R.A., McNabb, S., Lembo, T., Cleaveland, S., Marston, D.A., Horton, D.L., McElhinney, L.M. and Fooks, A.R. 2009. A robust lentiviral pseudotype neutralisation assay for rabies and lyssavirus serology. Rabies In The Americas XX. Quebec, Canada 2009

The implications for ‘in-field’ sero-surveillance and evaluation of vaccines targeting rabies using lacZ based lentiviral pseudotypes
Wright, E., McNabb, S., Goddard, T., Horton, D.L., Weiss, R.A., Cleaveland, S. and Fooks, A.R. 2009. The implications for ‘in-field’ sero-surveillance and evaluation of vaccines targeting rabies using lacZ based lentiviral pseudotypes. Society For General Microbiology Spring 2009 Meeting. Harrogate, UK 2009

Retroviral pseudotypes
Temperton, N.J. and Wright, E. 2009. Retroviral pseudotypes. in: Encyclopaedia of Life Sciences Chichester Wiley.

HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor
Chain, B.M., Noursadeghi, M., Gardener, M., Tsang, J. and Wright, E. 2008. HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor. Vaccine. 26 (45), pp. 5752-5759.

Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison
Wright, E., Temperton, N.J., Marston, D.A., McElhinney, L.M., Fooks, A.R. and Weiss, R.A. 2008. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. Journal of General Virology. 89 (9), pp. 2204-2213.

Duffy Antigen Receptor for Chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility
He, W., Neil, S., Kulkarni, H., Wright, E., Agan, B.K., Marconi, V.C., Dolan, M.J., Weiss, R.A. and Ahuja, S.K. 2008. Duffy Antigen Receptor for Chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host and Microbe. 4 (1), pp. 52-62.

A novel serological assay for the detection of rabies virus and lyssavirus neutralising antibodies
Wright, E., Temperton, N.J., Marston, D.A., Fooks, A.R. and Weiss, R.A. 2008. A novel serological assay for the detection of rabies virus and lyssavirus neutralising antibodies. Society For General Microbiology Spring 2008 Meeting. Edinburgh, UK 2008

The evaluation of antibody responses to rabies virus using retroviral pseudotypes and the implications for ‘in-field’ vaccine trials
Wright, E., Temperton, N.J., Marston, D.A., Fooks, A.R. and Weiss, R.A. 2008. The evaluation of antibody responses to rabies virus using retroviral pseudotypes and the implications for ‘in-field’ vaccine trials. BIT's First Annual World Vaccine Congress. Foshan, China 2008

A novel serological assay for detection of rabies virus neutralising antibodies
Wright, E., Temperton, N.J., Weiss, R.A., Marston, D.A., McElhinney, L.M. and Fooks, A.R. 2007. A novel serological assay for detection of rabies virus neutralising antibodies. Rabies In The Americas XVIII. Ciudad de Guanajuato, Mexico 2007

Characterisation of persistent viral infections in bats
Wright, E., Takeuchi, Y., Brookes, S., Fooks, A.R. and Weiss, R.A. 2007. Characterisation of persistent viral infections in bats. The First International Meeting on Emerging Diseases and Surveillance. Vienna, Austria 2007

Effect of Duffy antigen receptor for chemokine (DARC) polymorphisms on susceptibility to HIV infection and progression to AIDS
Wright, E., He, W., Neil, S., Kulkarni, H., Agan, B.K., Marconi, V.C., Dolan, M.J., Ahuja, S.K. and Weiss, R.A. 2007. Effect of Duffy antigen receptor for chemokine (DARC) polymorphisms on susceptibility to HIV infection and progression to AIDS. Institute Pasteur Genetics and Mechanisms of Susceptibility to Infectious Diseases. Paris, France 2007

Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells
Wright, E., Bain, M., Teague, L., Murphy, J. and Sinclair, J. 2005. Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells. Journal of General Virology. 86 (3), pp. 535-544.